ZA200208350B - Administration of a thiol-based chemoprotectant compound. - Google Patents
Administration of a thiol-based chemoprotectant compound. Download PDFInfo
- Publication number
- ZA200208350B ZA200208350B ZA200208350A ZA200208350A ZA200208350B ZA 200208350 B ZA200208350 B ZA 200208350B ZA 200208350 A ZA200208350 A ZA 200208350A ZA 200208350 A ZA200208350 A ZA 200208350A ZA 200208350 B ZA200208350 B ZA 200208350B
- Authority
- ZA
- South Africa
- Prior art keywords
- agent
- thiol
- arterial
- intra
- diagnostic
- Prior art date
Links
- 150000003573 thiols Chemical class 0.000 title claims description 103
- 150000001875 compounds Chemical class 0.000 title claims description 31
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 165
- 229960004308 acetylcysteine Drugs 0.000 claims description 165
- 239000003795 chemical substances by application Substances 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 112
- 238000002512 chemotherapy Methods 0.000 claims description 65
- 238000001361 intraarterial administration Methods 0.000 claims description 55
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 53
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 53
- 230000000694 effects Effects 0.000 claims description 52
- 238000011282 treatment Methods 0.000 claims description 50
- 210000004556 brain Anatomy 0.000 claims description 39
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 36
- 208000027418 Wounds and injury Diseases 0.000 claims description 31
- 229940127089 cytotoxic agent Drugs 0.000 claims description 31
- 230000006378 damage Effects 0.000 claims description 31
- 208000014674 injury Diseases 0.000 claims description 31
- 230000001225 therapeutic effect Effects 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000001472 cytotoxic effect Effects 0.000 claims description 25
- 239000002872 contrast media Substances 0.000 claims description 24
- 231100000433 cytotoxic Toxicity 0.000 claims description 23
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 239000002254 cytotoxic agent Substances 0.000 claims description 20
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 20
- 210000000056 organ Anatomy 0.000 claims description 20
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 19
- 229930182818 D-methionine Natural products 0.000 claims description 18
- 108010024636 Glutathione Proteins 0.000 claims description 18
- 229960003180 glutathione Drugs 0.000 claims description 18
- 229940124444 chemoprotective agent Drugs 0.000 claims description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 15
- JKRODHBGNBKZLE-YUMQZZPRSA-N (2s)-2-amino-5-[[(2r)-1-[(2-ethoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCOC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O JKRODHBGNBKZLE-YUMQZZPRSA-N 0.000 claims description 12
- 210000002376 aorta thoracic Anatomy 0.000 claims description 12
- 210000003734 kidney Anatomy 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 12
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 11
- 230000000116 mitigating effect Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000011275 oncology therapy Methods 0.000 claims description 11
- 239000008174 sterile solution Substances 0.000 claims description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 10
- 210000001367 artery Anatomy 0.000 claims description 9
- 210000001715 carotid artery Anatomy 0.000 claims description 8
- 229940098617 ethyol Drugs 0.000 claims description 8
- 239000011261 inert gas Substances 0.000 claims description 8
- 208000025440 neoplasm of neck Diseases 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229910052786 argon Inorganic materials 0.000 claims description 5
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 239000001307 helium Substances 0.000 claims description 5
- 229910052734 helium Inorganic materials 0.000 claims description 5
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 5
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 239000000138 intercalating agent Substances 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 230000003039 myelosuppressive effect Effects 0.000 claims description 2
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 40
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 39
- 229960001924 melphalan Drugs 0.000 description 39
- 238000001802 infusion Methods 0.000 description 36
- 230000001767 chemoprotection Effects 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 29
- 229960004562 carboplatin Drugs 0.000 description 28
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 28
- 230000003013 cytotoxicity Effects 0.000 description 25
- 231100000135 cytotoxicity Toxicity 0.000 description 25
- 238000012384 transportation and delivery Methods 0.000 description 24
- 230000004224 protection Effects 0.000 description 23
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 22
- 229960004316 cisplatin Drugs 0.000 description 22
- 229930012538 Paclitaxel Natural products 0.000 description 16
- 210000001772 blood platelet Anatomy 0.000 description 16
- 229960001592 paclitaxel Drugs 0.000 description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 230000001988 toxicity Effects 0.000 description 15
- 231100000419 toxicity Toxicity 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000008499 blood brain barrier function Effects 0.000 description 13
- 229960000752 etoposide phosphate Drugs 0.000 description 13
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 206010065553 Bone marrow failure Diseases 0.000 description 10
- 208000003174 Brain Neoplasms Diseases 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 239000003223 protective agent Substances 0.000 description 10
- 102000004046 Caspase-2 Human genes 0.000 description 8
- 108090000552 Caspase-2 Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 229910052697 platinum Inorganic materials 0.000 description 8
- 206010051779 Bone marrow toxicity Diseases 0.000 description 7
- 231100000366 bone marrow toxicity Toxicity 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 238000013042 tunel staining Methods 0.000 description 7
- 102000011727 Caspases Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004820 blood count Methods 0.000 description 6
- -1 conjugation Chemical compound 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108700024319 S-ethyl glutathione Proteins 0.000 description 4
- 230000002152 alkylating effect Effects 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000008816 organ damage Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100000155 toxicity by organ Toxicity 0.000 description 3
- 230000007675 toxicity by organ Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000000448 cultured tumor cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000007261 regionalization Effects 0.000 description 2
- 210000005227 renal system Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DQADPIOSMNGDGG-WCCKRBBISA-N (2r)-2-acetamido-3-sulfanylpropanoic acid;sodium Chemical group [Na].CC(=O)N[C@@H](CS)C(O)=O DQADPIOSMNGDGG-WCCKRBBISA-N 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 1
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010059440 Platelet toxicity Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 208000011861 acute hypotension Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000034404 cisplatin toxicity Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000441 effect on granulocytes Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229910052920 inorganic sulfate Inorganic materials 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010503 organ complication Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000201 platelet toxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 150000007970 thio esters Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940048910 thiosulfate Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ADMINISTRATION OF A THIOL-BASED CHEMOPROTECTANT COMPOUND
) The present application claims the benefit of the filing dates under 35 U.S.C. § 119(¢e) . to provisional U.S. Patent Application Serial No. 60/199,936 filed on April 26, 2000 and
Provisional U.S. Serial No. 60/229,870 filed on August 30, 2000, which are hereby incorporated by reference.
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
The present invention was partially supported under NIH grant No. NS33618 and by
The Department of Veterans Affairs merit review grant. The United States Government may have certain rights in this invention.
The present invention is based, in part, upon the discovery that a method of administration of N-acetylcysteine (NAC) markedly affects its effective biodistribution. The present invention provides a method for treating or mitigating the side effects, including organ damage, of cytotoxic cancer therapy for tumors located in the head or neck.
Additionally, NAC or other thiols can be administered concurrently with, before or after, intra-arterial procedures and provides protective affects to prevent or diminish organ damage.
N-acetylcysteine (NAC) is an analog of cysteine. When NAC is administered to a mammal it is deacylated and enters a cellular synthetic pathway for the production of glutathione. Glutathione is involved in the cellular pathways influencing a tumor’s resistivity to cytotoxic drugs. The cytotoxic properties of chemotherapeutic drugs can be enhanced by pretreatment with buthionine sulfoximine (BSO) thereby reducing intracellular glutathione.
However, reduction of intracellular gluthionine will potentiate systemic toxicities associated with chemotherapeutic drugs. Thus, this procedure is dose-limiting. For protection, the glutathione levels of “normal” cells have to be reestablished if BSO is used to potentiate the cytotoxic properties of cytotoxic cancer therapies (Kamer et al., Cancer Res. 47:1593-1597, ’ 1987; Ozols et al., Biochem. Pharm. 36:147-153, 1987; McLellan et al., Carcinogenesis , 17:2099-2106, 1995; and Shattuck et al., J. Parenteral Enteral Nutrition 24:228-233, 1998).
It may be possible to reduce the bone marrow toxicity of chemotherapeutic drugs by using sulfur-containing chemoprotective agents (thio, thiol, and thioether compounds) to mimic one or many of the activities of glutathione such as conjugation, free radical scavenging, and drug efflux via the multidrug resistance associated proteins. NAC and other thiol agents such as
STS have early detoxifying activity not related to the later increase in glutathione levels.
These early detoxifying effects occur because the thiols themselves mimic some actions of glutathione such as free radical scavenging, anti-oxidant activity, chemical conjugation, and . 5 activation of efflux pumps.
A potential problem with any chemoprotectant is the possibility of deactivating the anti-tumor effect of the chemotherapy or radiation therapy. The goal of chemoprotection is to reduce unwanted toxicities of chemotherapy or radiotherapy without affecting efficacy.
For brain tumor chemotherapy, one must attempt to increase the delivery of chemotherapy to the brain tumor and block the delivery of the chemoprotective agent.
Additionally, one will want to target the chemoprotectant agent to the bone marrow to protect against myelosuppression and to liver, kidney and lung to prevent organ toxicity. Therefore, there is a need in the art to improve pharmacokinetics and biodistribution of chemoprotectant agents so that they will be more effective when delivered in a tissue-specific manner.
Preferably, delivery is maximized to the bone marrow, chest and abdomen organs while minimized to the brain.
There are more than 10 specific active transport systems that transport compounds from the blood to the brain. Otherwise, substances, such as chemoprotectants can only nominally penetrate this barrier by passive diffusion. Brain tumors are particularly difficult to treat because the blood-brain barrier is an anatomical structure that limits the egress of constituents in the blood to the brain. Thus, brain tumors often respond poorly to chemotherapeutic drugs. There have been many attempts to try to increase brain bioavailability of various drug compounds to brain tissue. One technique uses osmotic BBB modification by administering mannitol through the internal carotid artery (Neuwelt et al.,
Cancer Res. 45:2827-2833, 1985). This technique is useful for administering the chemotherapeutic methotrexate to experimental brain tumors that would otherwise be inaccessible to this drug (it poorly crosses the BBB). The osmotic shrinkage caused by intracarotid mannitol administration allowed for temporary BBB disruption and increased ) tumor delivery of the methotrexate. Thus, a temporary disruption of the barrier functions of ) 30 the BBB can be induced by a sugar, such as mannitol, and cause higher brain concentrations of a drug compound that would not otherwise have crossed the BBB. This BBB opening technique has also been investigated with other chemotherapeutic drugs (Neuwelt et al., Proc.
Natl. Acad. Sci. USA 79:4420-4423, 1982; Fortin D. McCormich Cl, Remsen LG, Nixon R,
Neuwelt EA, “Unexpected neurotoxicity of etoposide phosphate when given in combination with other chemotherapeutic agents after blood-brain barrier modification using propofol for general anesthesia in a rat model,” Neurosurgery 47:199-207, 2000).
An example of chemoprotection is a drug neutralization technique described in U.S.
Patent 5,124,146 wherein excess toxic drug compounds are “mopped up” or bound by a . 5 binding or neutralizing agent not able to penetrate the blood brain barrier. This technique requires precise timing as to when the drug neutralizing agent is administered.
There are several thiol-based chemoprotectant agents that contain a thio, thiol, aminothiol or thioester moiety. Several thiol-based chemoprotectant agents have been shown to provide protection against at least some of the systemic toxicities caused by alkylating chemotherapeutics. The thiol based chemoprotective agents include N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, and thiol amifostine (Ethyol or WR2721). NAC is currently marketed in the United States under an orphan indication for oral and intravenous (i.v.) administration for overdosing with acetaminophen.
NAC has also been shown to be a chemoprotectant when administered in combination with a vanadate compound (U.S. Patent 5,843,481; and Yarbo (ed) Semin. Oncol. 10 [Suppl 1156-61, 1983). Ethyol is also marketed in the United States under the generic name of
Amifostine. GSH ethyl ester is an experimental thiol not yet marketed for clinical use, but is representative of the class of thiols that is converted directly to glutathione.
In addition, NAC has been shown to be a mucoregulatory drug used for the treatment of chronic bronchitis (Grassi and Morandini, Eur. J. Clin. Pharmacol. 9:393-396, 1976;
Multicenter Study Group, Eur. J. Respir. Dis. 61: [Suppl.]93-108, 1980; and Borman et al.,
Eur. J. Respir. Dis. 64:405-415, 1983).
In plasma, NAC can be present in its intact, reduced forms as well as in various oxidized forms. It can be oxidized to a disulfide by reacting with other low molecular weight thiols, such as cysteine and glutathione. NAC can be oxidized by reacting the thiol groups of plasma proteins. When administered intravenously, the brain levels of NAC are <5%. Yet,
NAC does cross the BBB if given by an intra-arterial route of administration. NAC is rapidly cleared from plasma via the liver and kidney. Moreover, NAC does not show neurotoxic ) properties.
There are bioanalytical methods for the determination of NAC in plasma, including
Cotgreave and Moldeus, Biopharm. Drug Disp. 8:365-375, 1987; and Johansson and
Westerlund, J. Chromatogr. 385:343-356, 1986 that also permit a determination of other forms of NAC. Moreover, cysteine and cystine have been identified as major metabolites of
NAC. The excreted urinary product is inorganic sulfate together with small amounts of taurine and unchanged NAC. According to the label indications for NAC manufactured by (American Regent Laboratories Shirley, NY), vials of NAC are produced as a sterile solution for oral administration diluted with water or soft drinks.
Another thiol-containing chemoprotectant is sodium thiosulfate (STS). Its chemical . 5 formula is Na,S,0; and it has been used clinically for cyanide poisoning and for nephrotoxicitiy caused by cisplatin. STS is cleared rapidly from circulation primarily by the kidney. The plasma half life after a bolus injection is about 17 minutes. STS can also inactivate platinum agents through covalent binding to platinum agents at a molar excess >40:1 (STS:platinum). With i.v. administration of STS, the brain levels of STS are <5% of blood showing poor brain localization. Neurotoxic side effects, in the form of seizures, may occur when brain levels of STS are enhanced through i.a. administration within 30 min of
BBB disruption.
Diagnostic or therapeutic procedures involving intra-arterial catheterization can cause a variety of organ toxicities, complications and side effects from injuries. For example, placement of an arterial catheter can dislodge plaques from artery walls that can lodge elsewhere in the vasculature causing ischemia. Ischemia increases the presence of free radicals and leads to cell death. As another example, nephrotoxicity of radiographic contrast agents can lead to acute renal failure even when measures are taken to reduce toxic effects.
As a third example, intra-arterial catheterization is used during angioplasty procedures wherein a balloon catheter is inserted into the arterial circulation and then threaded (with radiographic contrast agents for visualization) to a site of occlusion. In dilating the occluded artery, various forms of tissue damage and inflammatory reactions (e.g., restenosis) can occur including ischemic tissue injury.
Specifically, toxic side effects of intra-arterial catheterization and infusion of radiographic contrast agents prolong hospital stays, add to the cost of medical care, and can be fatal. The incidence of radiographic-contrast-agent-induced acute renal failure, currently estimated to be as high as 50 percent among patients with diabetes mellitus and preexisting renal disease who receive contrast agents, is likely to remain high as the use of invasive i intra-arterial procedures to diagnose and treat complex disease continues to grow.
Radiographic contrast agents are used in medical imaging. Medical imaging is the production of images of internal organs and tissues by the application of nonsurgical techniques. Contrast agents are chemicals used to enhance the image, and to increase contrast between the target organ and surrounding tissues. Prevention or mitigation of renal failure after the administration of a radiographic contrast agent has been notably difficult.
Calcium-channel antagonists, adenosine antagonists, and dopamine have all been used without convincing evidence of benefit.
Tepel et al. proposed the oral administration of approximately 1200 mg of
N-acetylcysteine per day, given orally in divided doses on the day before and on the day of ] 5 the administration of the radiographic contrast agent. (Tepel et al., New England J. Med.,
July 20, 2000). Oral administration allegedly prevented the expected decline in renal function in all patients with moderate renal insufficiency, and therefore high risk, who were undergoing computed tomography.
NAC has been used successfully to ameliorate the toxic effects of a variety of experimentally or clinically induced ischemia-reperfusion syndromes of the heart, kidney, lung, and liver. In each of these syndromes, it is thought that the activity of NAC is related to its action as a free-radical scavenger, or as a reactive sulphydryl compound that increases the reducing capacity of the cell. The specific mechanism of NAC to prevent the nephrotoxic effects of contrast agents is not known.
Therefore, there is a need in the art to find better ways to use thiol-based chemoprotectants, such as NAC and STS and to take advantage of their pharmacokinetic properties. There is also a need in the art to find better, higher dose cytotoxic treatment regimens for head and neck as well as brain tumors that avoid dose-limiting due to side effects.
There is a need in the art for a compound that can be used with intra-arterial catheterization procedures to reduce organ toxicity. Diabetic patients with markedly reduced renal function, in whom coronary angiography is often delayed because of the considerable risks to renal function entailed by angiography, may particularly be benefited by targeted delivery of a protectant agent. Additionally, there is a need in the art for a low cost compound which is generally available, easy to administer and has limited side effects.
There is a need in the art for a compound and a method of administration of the compound that can be used to reduce or eliminate tissue damage caused by intra-arterial procedures.
Additionally, there is a need in the art to find better ways to use thiol-based ’ radiographic protectants, such as NAC and STS (sodium thiosulfate) and to take advantage of their pharmacokinetic properties. There is also a need in the art to find an agent protective against intra-arterial catheterization-induced reductions in organ function. These and other problems of the prior art are solved by the present method and pharmaceutical composition.
The present invention provides a method and compound for locally administering a ] thiol based chemoprotectant to treat or mitigate the side effects of cytotoxic cancer therapy for brain tumors located in the head or neck. Further, the present invention provides a . 5 method and compound for locally administering a thiol-based chemoprotectant to an organ or tissue to protect against injury from diagnostic or therapeutic intra-arterial procedures. The method includes administering a thiol-based chemoprotectant agent intra-arterially in conjunction with, before, or after administration of a cytotoxic agent.
In one embodiment, the cytotoxic agent is a cancer chemotherapeutic agent. The cytotoxic agent is dose-limited due to myelosuppressive effects systemically. The cancer chemotherapeutic agent is selected from the group consisting of cis-platinum compounds, taxanes (e.g., paclitaxel), steroid derivatives, anti-metabolites, vinca alkaloids, adriamycin and doxorubicin, etoposide, arsenic derivatives, intercalating agents, alkylating agents (such as melphalan) and combinations thereof. The cytotoxic agent is administered within eight hours (before, during or after) of the thiol-based chemoprotectant agent administration. In yet another embodiment, when the tumor is located in the head or neck or brain, the cytotoxic agent is administered such that the majority of the dose is directed to the head or neck region.
Preferably, the thiol-based chemoprotectant agent is a compound selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof. In one embodiment, the thiol-based chemoprotectant agent is administered in a pyrogen-free sterile solution by a catheterization procedure via a catheter having a tip that is located in the descending aorta. In yet another embodiment, the dose of the thiol-based chemoprotectant agent per procedure is from about 200 mg/m’ to about 40 g/m”. Most preferably, the dose of NAC agent per procedure is from about 400 mg/m’ to about 1200 mg/m’ and the dose of STS is from about 5 g/m’ to about 40 g/m’ .
In one embodiment, the intra-arterial catheter is positioned in an artery providing blood flow to a potential site or organ of injury. In yet another embodiment, the intra-arterial administration is at a site in the descending aorta. In yet another embodiment, the injury is caused by injecting a cytotoxic agent including a radiographic contrast agent using an intra-arterial catheter.
In yet another embodiment, the thiol-based chemoprotectant agent is administered in a pyrogen-free, non-oxidized sterile solution having a reducing agent, a buffer to maintain pH at or near physiologic pH and a metal chelating agent to bind metal ions that can catalyze oxidation of the thiol-based chemoprotectant agent. Preferably, the reducing agent is selected from the group consisting of vitamin E, tocopherol, dithiotreitol, mercaptoethanol, glutathione, and combinations thereof. Preferably, the buffer is one that is relatively ) 5 non-toxic and can maintain a pH of between 6 and 8 (e.g., phosphate buffer, Tris buffer).
Preferably, the thiol-based chemoprotectant agent is stored in a vial having a blanket of an inert gas. Most preferably, the inert gas is selected from the group consisting of argon, helium, nitrogen and mixtures thereof.
The present invention further provides a pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures, and for head and neck brain tumors. The compound includes a first agent for intra-arterial administration and a second agent administered intra-arterially.
Preferably the second agent is a thiol-based chemoprotectant agent. In one embodiment, the second agent is administered to the descending aorta or further downstream.
The first agent is administered to a carotid or vertebral artery. The first agent is a radiographic contrast agent delivered intra-arterially to position a catheter. In one embodiment, the first agent is administered within eight hours (before, during or after) of the second agent. The second agent is administered immediately after intra-arterial catheterization, prior to radiographic contrast agent, to within eight hours of the radiographic contrast agent.
In one embodiment, the second agent is administered in a pyrogen-free, sterile solution. In further embodiments, the solution is non-oxidized and has a reducing agent, a buffer to maintain pH at or near physiologic pH and a metal chelating agent to bind up metal ions that can catalyze oxidation of the thiol-based chemoprotectant agent. Preferably, the reducing agent is selected from the group consisting of vitamin E, tocopherol, dithiothreitol, mercaptoethanol, glutathione, and combinations thereof. Preferably, the buffer is one that is relatively non-toxic and can maintain a pH of between 6 and 8 (e.g., phosphate buffer, Tris buffer). ’ In one embodiment, the thiol-based chemoprotectant agent is stored in a vial having a blanket of an inert gas. Most preferably, the inert gas is selected from the group consisting of argon, helium, nitrogen and mixtures thereof. Preferably, the thiol-based chemoprotectant agent is a compound selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
Preferably, the dose of the thiol-based chemoprotectant agent per procedure is in the range of
200 mg/m? to 2000 mg/m’. In a further preferred embodiment, the dose of NAC per procedure is in the range of 400 mg/m? to 1200 mg/m’.
Further, one advantage of NAC is that it is protective against multiple intra-arterial procedure toxicities, including but not limited to those caused by radiographic contrast ] 5 agents.
The methods and compounds will best be understood by reference to the following detailed description of the preferred embodiment, taken in conjunction with the accompanying drawings. The discussion below is descriptive, illustrative and exemplary and 1s not to be taken as limiting the scope defined by any appended claims.
Figure 1 shows an anatomical diagram of major arteries and the top level for placing the catheter for administration of the thiol-based chemoprotectant agent.
Figure 2 (A-C) shows the effect of bone marrow recovery and lower nadirs using the left carotid aortic infusion inventive method with chemotherapy and the chemoprotectant
NAC. Specifically, Figure 2A shows the effect on white blood cells, Figure 2B the effect on platelets and Figure 2C the effect on granulocytes.
Figure 3A shows dose/response for N-acetylcysteine chemoprotection. Figure 3B shows dose/response for D-methionine chemoprotection. Cytotoxicity was assessed in cultured
LX-1 SCLC cells, 1x104 cells per well in 96 well plates, using the WST colorometric assay.
Cells were treated with approximately 90% lethal dose of chemotherapy (melphalan = 20 ug/ml, carboplatin = 200 pg/ml, cisplatin = 20 ug/ml). Chemoprotectant was added at the indicated concentration of N-acetylcysteine shown in Figure 3A or D-methionine shown in
Figure 3B either alone (n) or immediately following chemotherapy. Data are expressed as the percentage of live cells compared to untreated control samples (without chemotherapy) and each point represents the mean + standard deviation of 4 wells.
Figures 4A and 4B show cytoenhancement and chemoprotection. Figure 4A shows the effect of BSO and N-acetylcysteine on Carboplatin cytotoxicity. Figure 4B shows the effect of . BSO and N-acetylcysteine on etoposide phosphate cytotoxicity. Cytotoxicity was assessed in cultured LX-1 SCLC cells, 1x104 cells per well in 96 well plates, using the WST colorometric ' 30 assay. BSO cytoenhancement consisted of preincubation at 100 pM BSO for 18 hours. The chemoprotective agent was added immediately after chemotherapy. The experimental conditions were dose/responses for chemotherapy (carboplatin or etoposide phosphate) alone ( m ), BSO cytoenhancement ( &£ ), N-acetylcysteine rescue, (1000 pg/ml N-acetylcysteine, n ),
or BSO cytoenhancement and N-acetylcysteine rescue (u ). Data are expressed as the percentage of live cells compared to untreated control samples without chemotherapy and each point represents the mean + standard deviation of 4 wells.
Figure 5 shows cytoenhancement and chemoprotection in fibroblasts. Cytotoxicity was . 5 assessed in GM294 human fibroblasts, 1x104 cells per well in 96 well plates, using the WST + colorometric assay. Cells were pretreated with or without BSO, 100 pM for 18 hours prior to addition of chemotherapeutics (melphalan = 10 pg/ml, carboplatin = 100 pg/ml, cisplatin = 7.5 pg/ml, etoposide phosphate 100 pg/ml) either alone (open bar), or with N-acetylcysteine rescue, (1000 pg/ml N-acetylcysteine, striped bar), BSO cytoenhancement (black bar), or BSO cytoenhancement and N-acetylcysteine rescue (cross hatched bar). Data are expressed as the percentage of live cells compared to control samples (without chemotherapy) and each point represents the mean = s.d. of 4 wells.
Figure 6 shows time dependence for rescue of chemotherapy cytotoxicity.
Chemotherapy cytotoxicity was assessed in cultured LX-1 SCLC cells (1x104 cells/well in 96 well plates) using the WST colorometric assay. Cells were treated with melphalan at 20 pg/ml, carboplatin 200 pg/ml, cisplatin 10 pg/ml, or etoposide phosphate 200 pg/ml. Cells then received either no protectant (open bars), or sodium thiosulfate, 2000 pg/ml, added immediately (striped bars), 2 hours (black bars) or 4 hours (cross hatched bars) after chemotherapy. Data are expressed as the percentage of live cells compared to control samples (without chemotherapy) and each point represents the mean + standard deviation of 4 wells.
Figures 7A and 7B show the effect of cytoenhancement and chemoprotection on apoptosis. Figure 7A shows caspase-2 enzymatic activity. Figure 7B shows TUNEL staining for DNA fragmentation. Apoptosis was assessed in cultured LX-1 SCLC cells pretreated for 18 hours with or without 100 uM BSO. The experimental conditions were no addition (open bars), melphalan (10 pg/ml, striped bars) or melphalan (10 pg/ml) plus N-acetylcysteine (1000 pg/ml) (cross hatched bars) for 20 h prior to harvest. Caspase-2 activity is expressed as percentage activity in untreated control samples (mean * standard deviation, n = 3). TUNEL staining is expressed as the percentage of cells showing positive staining. ' Figure 8 shows the resuits of NAC delivery to rat brain. Radiolabeled NAC in , 30 combination with unlabeled low dose NAC (140 mg/kg) or high dose NAC (1200 mg/kg) was administered to rats with the following routes of infusion: 1.v. (open bars), intra-arterially into the right carotid artery (striped bars), intra-arterial via the left carotid artery with left internal artery occlusion (aortic infusion) (black bars), and intra-arterial (right carotid) with
BBBD (cross hatched bars). Radiolabel in tissue homogenates is expressed as the mean and standard error of the % administered dose of 14C-NAC per gram of tissue (n = 3 rats per group). Significant differences from i.v. delivery are indicated by *P<.05 and **P<.001.
Figure 9 represents tests showing the effect of NAC route of administration on ) 5 mortality +/- BSO. A Kaplan-Meier product limit analysis was used to evaluate the mortality due to chemoprotection with NAC. Rats were treated with or without BSO (10 mg/kg i.p. b.i.d. x 3, black bars) prior to treatment with chemotherapy (Carboplatin 200 mg/m2, etoposide phosphate 100 mg/m2, melphalan 10 mg/m2). Chemoprotection consisted of NAC (1200 mg/m2) or NAC (1000 mg/m2) plus STS (8 g/m2) given either i.v. (n=17 BBSO, n= 8 10 +BSO) or by aortic infusion (n = 19 BBSO, n = 28 +BS0O). P=0.0014 by Wilcoxon analysis.
Figures 10A-10D show the results of tests on chemoprotection for chemotherapy- induced myelosuppression. Rats received tri-drug chemotherapy (Carboplatin 200 mg/m2, etoposide phosphate 100 mg/m2, melphalan 10 mg/m2), with (triangles, squares) or without (circles) chemoprotection. Blood counts were determined prior to chemotherapy, at the blood nadir (6 days), and in the recovery phase (9 days after treatment). Chemoprotection was with
NAC (1200 mg/kg) administered via aortic infusion 30 min prior to chemotherapy (triangles) or NAC prior to chemotherapy and STS (8 g/m2) immediately after chemotherapy (squares).
In Figure 10B and Figure 10D animals received BSO (10 mg/kg i.p. x 3 d) prior to treatment with chemotherapy. Panel A shows granulocyte counts without BSO Figure 10B shows granulocyte counts with BSO (mean +/- SEM, n = 6 per group) Figure 10C shows platlet count without BSO Figure 10D shows platlet count with BSO. Significant difference from the no protectant groups were determined by Wilcoxon/Kruskal-Walliis rank sums tests (* p<0.05, ** p<0.01).
The present method includes administration of at least two different agents for treating brain or head and neck tumors. The first agent is a cytotoxic agent. In one example, the cytotoxic agent is radiation or a chemotherapeutic agent. The radiation or chemotherapeutic agent generally has a dose-limiting systemic side effect of ’ myelosuppression. If myelosuppression is too severe, it is life threatening as the patient is unable to generate enough white blood cells of multiple lineages to coordinate immune surveillance function for defending against pathogen attack. Therefore, any ability to reduce bone marrow toxicity or myelosuppression will allow for greater and more effective administration of the cytotoxic agent.
Current treatment to reduce bone marrow side effects include recombinant growth factors that are lineage-specific. Such growth factors have included EPO (erythropoietin) for red cells and G-CSF (granulocyte colony stimulating factor) or GM-CSF (granulocyte macrophage colony stimulating factor) for various lineages of infection-fighting white cells. . 5 In addition, TPO (thrombopoietin) is in clinical trials for augmenting a platelet response in myelosuppressed patients. However, such growth factors act to stimulate lineage specific precursor cells to divide and mature down lineage-specific paths. Thus, the use of growth factors results in a more rapid recovery from bone marrow toxicity but does not generally reduce the nadir of toxicity. Such growth factors have been able to allow a patient to tolerate a greater number of cytotoxic treatments (where myelosuppression is a limiting toxicity), but generally not higher doses of the cytotoxic agent administered.
The method allows for greater doses of the cytotoxic agent directed to head and neck tumors. Specifically, the cytotoxic agent (if it 1s a chemical compound or combination of compounds) is administered intra-arterially such that it is directed initially to the head and neck circulation. Thus, the highest concentration of cytotoxic agent is direct to the location of the tumor to be treated. By contrast, iv administration provides for the same concentration of cytotoxic agent in the bone marrow, where side effects happen, as systemic dose.
Thiol-based chemoprotectant agents are nonspecific chemoprotectant agents. They are not specific to “normal” tissue or cells but can protect both normal and tumor tissue.
Earlier attempts to utilize the chemoprotectant properties of thiol-based chemoprotectant agents have failed due to the fact that they were administered either orally or systemically, they were rapidly metabolized, and protected both normal and tumor tissue. Systemic administration includes iv.
The method includes utilizing a spatial two-compartment pharmacokinetic model which results in a general tissue first pass effect to prevent significant or chemoprotectant doses of thiol-based chemoprotectant agents from gaining general systemic circulation through the venous circulatory system. The method utilizes only one pass going to tissues below the level of the heart in order to effect a chemoprotectant effect. Therefore, head and ' neck tumors are treatable through regionalization of doses of the cytotoxic agent to the brain or head and neck where the tumor tissue is located and doses of the chemoprotectant to general tissues below the level of the heart where the majority of bone marrow tissue is located.
The ability of a thiol-based chemoprotectant agent to show a first pass effect through non-liver tissue was surprising. Once any thiol-based chemoprotectant agent that is not tissue-absorbed gains access to the venous circulation, it will be cleared through a liver first pass or rapidly removed through renal clearance. When administered not according to the method described, NAC is actively transported across the BBB. An example of spatial compartmentalization is the administration of a thiol-based chemoprotectant agent into the . 5 descending aorta or lower preventing any significant chemoprotectant concentrations of the thiol-based chemoprotectant agent from ever reaching the brain or head or neck region where the tumor tissue is located. Spatial compartmentalization is facilitated by the rapid tissue uptake of the thiol-based chemoprotectant agent. Spatial compartmentalization is needed in order to achieve any meaningful therapeutic benefit with a thiol-based chemoprotectant agent. Without spatial compartmentalization, the undesirable result of the thiol-based chemoprotectant agent protecting the tumor tissue will occur. In the case of NAC as the thiol-based chemoprotectant agent, passage of the BBB by NAC will restore glutathione levels to the brain tumor, thereby increasing the tumor’s resistance to cytotoxic drugs.
The ability to set up a two-compartment pharmacokinetic model was discovered 1S through a series of experiments using in vitro and in vivo models and administering both chemotherapeutic agents and the thiol-based chemoprotectant agents NAC and STS.
However, it should be noted that radiation therapy can be similarly localized or even more easily localized than chemotherapeutic agents. Tissue culture pharmacological studies have shown that treatment with NAC and STS can reduce cell killing by the chemotherapeutics melphalan, carboplatin, and cisplatin. The in vivo results show that localized NAC or STS administration resulted in less myelosuppression and faster recovery from chemotherapy.
Moreover, synergistic results were observed with the combination of thiol-based chemoprotectant agent NAC and STS providing evidence for a combination of thiol-based chemoprotectant agents to enhance the protective role when the combination of thiol-based chemoprotectant agents is administered according to the inventive process.
As shown in Figure 1, in another embodiment of the method, a thiol-based chemoprotectant agent is administered intra-arterially such that it is directed systemically.
This provides the highest concentration of thiol-based chemoprotectant agent to the location ' of organ damage, for example the kidneys, to protect against reduction of renal function.
Oral administration, by contrast, provides for general systemic administration with the concentration of protective agent going elsewhere in the body, mainly the liver, and requiring higher dosages so as to provide a sufficient dose at the kidney (often the site of organ damage for radiographic contrast agents). In addition, the thiol-based chemoprotectant agent is not specific to normal tissue or cells but can protect both normal and tumor tissue.
The method is based upon results obtained utilizing a spatial two-compartment pharmacokinetic model that resulted in a general tissue first pass effect to prevent significant or radiographic-protectant doses of thiol-based radiographic-protectant agents (specifically illustrated are NAC and STS) from gaining general systemic circulation through the venous ] 5 circulatory system. Thus, there was a surprising need for only one pass going to tissues of the renal system. This result prevented decreased renal function through regionalization of doses of the radiographic agent to the area where radiography is to be performed and doses of the protectant to the renal system.
As shown in Figure 1, a catheter was inserted into the circulatory system generally via the femoral artery. In the first embodiment, a catheter is inserted into the body and administers a dosage of radiographic contrast agent into the body. An effective dosage of the thiol-based protective agent, preferably NAC, is administered at any time from immediately after the intra-arterial catheterization, preferably before contrast agent, to within about eight (8) hours after the administration of the radiographic contrast agent. The catheter for delivery ofthe radiographic protective agent is preferably inserted into the arterial system downstream of the aorta and directed in the mesenteric artery system. The thiol-based protective agent is introduced into the body at any time within about 5 hours after administration of the radiographic contrast agent to reduce or eliminate renal failure or decrease in renal function associated with administration of a renal contrast agent.
In a further embodiment, a catheter is inserted into the circulatory system (e.g., femoral artery) and administers an effective dosage of a thiol-based protective agent into the body. A radiographic contrast agent is administered by the same catheter and is used to position the catheter to the appropriate place for the therapeutic or diagnostic procedure. The thiol-based protective agent is introduced into the body, generally via the same arterial catheter, at any time within about 5 hours before or after administration of the radiographic contrast agent. Preferably, the thiol-based protective is administered via the arterial catheter one or a plurality of times during the procedure.
Pharmaceutical Formulations ) : Techniques for the formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co.,
Easton, PA, latest addition. Suitable routes of administration are intra-artenal.
The compositions and compounds of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. . 5 For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers, such as Hank's solution, Ringer's solution, or physiological saline buffer. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulary agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. In one embodiment, a reducing agent or an anti-oxidant agent is added to the formulation of the thiol-based protective agent to prevent oxidation of the thiol-based protective agent. The antioxidant may include, but is not limited to, vitamin E, tocopherol, dithiotreitol, mercaptoethanol, glutathione. In one embodiment, an inert or non-oxidizing gas is added to a vial for intra-arterial administration.
Examples of such gasses are nitrogen, argon, helium, and combinations/mixtures thereof. : A therapeutically effective dose refers to that amount of the compound that results in areduction in the development or severity of myelosuppression. In another embodiment, toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical, pharmacological, and toxicological procedures in cell cultures or experimental animals, e.g., for determining the LDso (the dose lethal to 50% of the population) and the EDs (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LDsp and EDsg. Compounds that exhibit high therapeutic indices are preferred. The data obtained from cell culture assays or animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies . 5 preferably within a range of circulating concentrations that include the EDs, with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g.
Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1).
The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
According to the method, a thiol-based chemoprotectant agent is administered intra-arterially in order for systemic tissues to be exposed to an initial dose of the thiol-based chemoprotectant agent in high enough concentration to provide a chemoprotective effect and to bypass the venous circulation and be eliminated by the liver. NAC is actively transported across the BBB. In one embodiment, to prevent access to the brain, after a transfemoral carotid/vertebral artery catheter is placed to perfuse the brain, the catheter can then be subsequently retracted and placed in the descending aorta for NAC infusion, thus performing a single surgical procedure with one catheter. This allows for minimal risk from arterial catheter procedures only and for high concentrations of NAC to be delivered to peripheral tissues and organs but not to brain and head.
Synthesis
Each thiol-based chemoprotectant agent, such as NAC or STS, can be synthesized by convention methods and are commercially available as a sterile solution.
Example 1
This example shows the results of an in vivo experiment in rats having a catheter implanted in the descending aorta for NAC administration. The rats were set up for drug ‘ administration by pushing a catheter forward past the junction of the external and internal carotid arteries (toward the aorta), and temporarily sealing off the internal carotid for good measure so nothing goes to the brain (left carotid aortic infusion method). In patients where entry is via the femoral artery and the catheter is threaded through the aorta to get to the brain in the first place, one would just pull the catheter back to the aorta to do the NAC infusion.
Rats were treated with carboplatin (200 mg/m), melphalan (10 mg/m’) and etoposide phosphate (100 mg/m?). In the NAC animals, NAC was infused with the left carotid aortic infusion method immediately after the chemotherapeutic agents, at concentrations ranging from 400-1200 mg/m®. White blood cells (wbc) and platelets (plt) were counted at baseline ) 5 before the experiment and at 6 and 9-11 days after treatment with the chemotherapeutic . agents. The animals that did not receive NAC were tested on day 9-10 while the NAC animals were tested on day 10-11. Counts are in 1000s per pul blood. These data in the initial experiment shown in Table 1 provide initial results without a white blood cell effect. The lack of white blood cell effect was not repeated as there were significant effects shown below.
Table 1 chemo alone wbc base wbcd6 wbc d9/10 pltbase pltd6 pltd9/10 mean 11.4 0.8 3.2 778 63 164 +/- sd +/- 41 +/-02 +/- 1.6 +/- 233 +/- 59 +/-91 number 8 4 3 7 4 3 chem +NAC wbcbase wbcd6 wbc d10/11 pltbase pltd6 pltdl10/11 mean 7.9 0.5 4.8 817 101 1232 ** +/- sd +- 21 +/-02 +/-07 +/- 142 +/- 48 +/- 167 number 5 4 3 5 4 3
The data in table 2 show additional results. In the NAC animals, NAC was infused by the left carotid aortic infusion method 30 min prior to chemo, at a concentration of 1200 mb/m2. White blood cells (wbc) and platelets (pit) were counted at baseline before the experiment and at 6 and 9 days after treatment with the chemotherapeutic agents. The data in
Table 1 show that NAC treatment decreased the nadir blood count for both white cells and platelets, and blood counts recovered from chemotherapy faster.
Table 2 i chemo wbc base wbc d6 wbc d9 plt base plt d6 plt d9 alone mean 6.4 1.6 5.2 878 187 599 ) +/- sd +/- 0.3 +/-0.4 +/- 0.7 +- 46 +/- 70 +/- 187 number 6 6 6 6 6 6 chem wbc base wbc d6 wbc d9 plt base plt d6 plt d9 +NAC mean 5.1 33 6.2 721 388 1155 . +/- sd +/- 0.4 +/- 0.7 +/- 1.6 +/- 59 +/- 95 +/- 154 number 6 6 6 6 6 6
These data show that with NAC the platelets recovered from chemotherapy faster.
In addition, the experiment with the same chemotherapy agents at the same doses with and without BSO (buthionine sulfoximine) shows improved white blood cell recovery and higher nadirs with the chemoprotectant (NAC alone or with STS at the doses listed above) in
Figure 2A. Similar data are shown with platelets in Figure 2B, and with granulocytes in
Figure 2C.
Example 2
This example shows the results of NAC delivery by different means of catheter-based administration. In this experiment, radiolabeled NAC was administered to rats by three different routes. Liver and kidney tissue, in addition to the ipsilateral and contralateral hemispheres of the brain, were analyzed for radioactivity. Results are shown as the percent of the injected radioactive dose per gram of tissue. Route indicates intravenous (1.v.), intra-arterial into the right carotid artery (i.a.), or left carotid with internal artery occlusion and aortic infusion (left carotid aortic infusion). The left carotid aortic infusion intra-arterial method uses descending aorta placement of the catheter tip and NAC administration. route left hem right hem liver kidney number
Lv. 0.02 0.03 0.59 0.72 2 ia 0.03 0.41 057 0.70 3
Left carotid aortic infusion 0.04 0.04 0.29 1.42 2
These data show that i.a. delivery provided much brain delivery in the infused . 25 hemisphere. When the NAC was administered i.v., negligible amounts were found in brain (0.03 % of the injected dose, n=2). When radiolabeled NAC was administered intraarterially . into the right carotid artery of the rat, high levels of radiolabel were found throughout the right cerebral hemisphere. Delivery was 0.41% of the injected dose (n = 3), comparable to the levels found in liver (0.57 % of the injected dos&) or kidney (0.70 % of the injected dose).
In contrast, the left carotid aortic infusion method prevented brain delivery. The Left carotid aortic infusion method also changed bio-distribution in peripheral tissues in that liver delivery was decreased and kidney delivery was increased. The change in tissue delivery with different modes of administration is likely due to NAC being related to the amino acid cysteine that is rapidly bound by tissues via the amino acid transporters. In summary, the , 5 method of administration of NAC markedly affected its biodistribution.
Example 3
This example tested whether the inventive method for intra-arterial infusion (via the left carotid artery, with left internal artery occlusion) could reduce brain delivery of NAC and increase systemic delivery. Brain delivery was 0.04 % of the injected dose with the inventive method (n=2).
In conjunction with other pharmacological and physiological data, these results show that NAC is protective when N-acetylcysteine is administered prior to, (preferably 30 minutes prior to), the cytotoxic agent at a dose which provides a serum concentration of NAC of between 0.5 mM to 15.0 mM, preferably 5S mM to 12.5 mM. Generally, a dose of between 40.0 mg/kg to 1000 mg/Kg of N-acetylcysteine will provide an appropriate serum concentration in humans and other mammals.
Example 4
This example shows the inventive process being used to compare bone marrow toxicity of a chemotherapeutic agent (alone or in combination) to administration of NAC alone (1000-1200 mg/m? alone or in combination) and NAC plus STS. The chemotherapy agents were carboplatin (200 mg/m?) melphalan (10 mg/m?) and etoposide phosphate (100 mg/m?). The dose of STS in the rat was 8 g/m’ that is the equivalent to 20 g/m? in humans.
The method of administration was left carotid aortic infusion method. These data are expressed according to lineages of bone marrow cell in Table 3a and 3b.
Table 3a wbc wbc wbc Platelet Plt plt chemo mean 9.2 0.7 3.2 759.0 63.3 164.0 sd 3.6 0.2 1.6 260.5 59.0 91.0 . n 7 4 3 7 4 3 wbc wbc Whbc Platelet Plt plt . chemo + mean 7.1 1.4 5.2 772.3 132.0 1559.0 sd 2.7 1.1 1.7 171.5 36.8 567.1 n 4 2 2 4 2 2 wbc wbc wbc Platelet Plt plt chemo + mean 9.5 2.8 8.6 936.5 554.0 1950.0
NAC+ sd 6.0 0.4 3.6 186.0 147.1 134.4 n 2 2 2 2 2 2
E Table 3b . chemo+ whbc base wbc db wbc d9 plt base plt do plt d9
BSO mean 6.8 0.8 54 930 92 387 +/- sd +7- 0.8 +/- 0.2 +/- 1.1 +/- 63 +/- 28 +/- 139 number 11 11 6 11 11 6
BSO+chem wbc base wbc d6 wbc d9 plt base plt d6 plt d9 +NAC mean 8.4 22 7.6 818 341 1560 +/- sd +/- 1.5 +/-0.3 +/-1.2 +/- 99 +/- 79 +/- 194 number 9 9 6 9 9 6
These data show the synergistic effect of a combination of STS and NAC as the combined thiol-based chemoprotectant agents administered according to the inventive process.
Example 5
This example provides the results of an in vitro experiment using a combination of a taxane (paclitaxel) with a paclitaxel-cytotoxic enhancing agent BSO and a ’ glutathione-reviving agent NAC in cultured tumor cells. Paclitaxel is cytostatic in cultured cells at concentrations from 1 to 10 micromolar, that is, the tumor cells do not grow but they are not killed either. At 20 uM, paclitaxel begins to be cytotoxic and at 30 uM it is completely toxic in cultured tumor cells. When the tumor cells were pretreated cells with BSO, paclitaxel addition was completely cytotoxic in vitro at doses as low as 5 uM.
NAC did not change the dose response for paclitaxel alone. However, NAC completely reversed the enhanced toxicity from the BSO treatment, returning paclitaxel concentration effects to the non-BSO level. This experiment was repeated twice with the data provided in Table 4. . 5 Table 4
Treatment paclitaxel dose live cells (WST fluorescence) paclitaxel alone 5 1.274 +/- .071 20 0.771 +/- .056 paclitaxel + NAC 5 1.369 +/- .061 20 0.823 +/- .094
BSO + paclitaxel 5 0.056 +/- .004 ** 20 0.045 +/- .004 **
BSO + paclitaxel + NAC 5 1.419 +/- .095* 20 0.732 +/- .100 * * significantly different from BSO and paclitaxel - ** significantly different from paclitaxel alone
Example 6
Chemoprotection against cytotoxicity
The dose/response for rescue from chemotherapy cytotoxicity was evaluated for four different small molecular weight sulfur containing chemoprotectants. Each chemotherapeutic agent was used at a concentration affording approximately 90% lethality in the absence of
BSO (20 pg/ml melphalan, 200 pg/ml carboplatin, 15 pg/ml cisplatin). Over all, N- acetylcysteine was the most effective of the thiol agents tested, on a pg/ml basis. The concentration dependence for protection with N-acetylcysteine in comparison to D- methionine is shown in Figures 3A and 3B, and Table 5 shows the EC50 for protection afforded by each protective agent. As shown in Figure 3A AND Table 5, the cytotoxicity of , | each alkylator was reduced by 75-90% by concurrent administration of N-acetylcysteine, but
N-acetylcysteine was more active against melphalan (EC50 = 74 + 18 pg/ml) than the
R 30 platinum agents. In contrast, as shown in Figure 3B and Table 5, D-methionine did not protect against melphalan toxicity at the doses tested (50 to 1000 pg/ml), although it was highly protective against cisplatin toxicity, with a half-maximal concentration of 140 + 41 pg/ml. The maximum magnitude of protection was variable between experiments, ranging from about 70% to 100% protection, and protection was consistently less for carboplatin than for cisplatin or melphalan. All agents tested required a significantly higher dose to protect against carboplatin than against cisplatin or melphalan. On a pg/ml basis, glutathione ethyl ester was the least effective protective agent. ) 5 Chemotherapy agents were fixed at the 90% lethal dose for each agent. Each EC50 measurement comprised 6 concentrations with 4 wells per concentration, and each dose response was performed twice for each protectant. EC50 concentrations, in pg/ml are reported as the average + pooled standard deviation for two independent experiments. For the combination of D-methionine with melphalan, protection was not detected. For each chemoprotectant, t test comparisons were done for melphalan versus cisplatin, cisplatin versus carboplatin, and carboplatin versus melphalan, and significant differences are indicated (** = P<0.01; *** = P<(0.001).
TABLE 5
Protection against chemotherapy cytotoxity
Chemoprotective agent EC50 (ug/ml) chemotherapy = N-acetylcysteine Sodium D-methionine ~~ Glutathione ethyl thiosulfate ester
Melphalan 74 + 18 *** 110+ 78 None *** 303 £124 **x*
Cisplatin 151+ 15 ** 86+ 76 ** 140 + 4] *** 530 £ 30 ***
Carboplatin 200 £ 15 *** 442 + 203 ** 379 £ 123 *** 995 + 48 ***
Example 7 Cytoenhancement and chemoprotection in combination
The effects of BSO cytoenhancement and thiol chemoprotection on the dose/response relationships for cytotoxicity of the alkylating chemotherapeutics were evaluated in the B.5
LX-1 cells. BSO cytoenhancement consisted of preincubation with 100 pM BSO for about 18-24 hours prior to addition of chemotherapy, and rescue consisted of 1000-2000 pg/ml of iy 25 thiol chemoprotectant added immediately after chemotherapy. As shown in Figure 4A and
Table 6, BSO consistently decreased the EC50 for cytotoxicity and increased the maximum degree of toxicity. The specific case of carboplatin and N-acetylcysteine is shown in Figure 4A. Glutathione depletion with BSO increased carboplatin cytotoxicity, reducing the EC50 by 48% (P<0.01). As detailed in Table 6, similar BSO cytoenhancement was found with melphalan (53% reduction of EC50, P<0.001), while the EC50 for cisplatin was reduced only
29% (P<0.05). Chemoprotection with N-acetylcysteine blocked carboplatin toxicity as well as BSO-enhanced cytotoxicity. Similar chemoprotection was found with additional thiol agents, sodium thiosulfate and glutathione-ethyl ester, but D-methionine was only effective 3 against the platinum agents. } 5 Cytoenhancement and chemoprotection against non-alkylating chemotherapeutic agents was also evaluated. As shown in Figure 4B, Glutathione depletion with BSO did not increase the cytotoxicity of etoposide phosphate, nor did N-acetylcysteine decrease the cytotoxicity of etoposide phosphate. Similarly, no enhancement or protection was found with methotrexate or doxorubicin in the B.S LX-1 cells, although carcinoma cells of gastric origin showed some enhancement with BSO (data not shown). Interestingly, although the growth inhibitory dose of taxol (approximately 10 nM) was not altered by BSO, glutathione depletion did shift the cytotoxic dose of taxol from 15 pM to 2 pM, and this enhanced cytotoxicity was completely reversed with N-acetylcysteine (not shown).
Whether the cytoenhancement and chemoprotection seen in the B.5 LX-1 SCLC cells was a generalized phenomenon was evaluated by testing similar experimental conditions in the GM294 human fibroblast cell strain. Cells were treated with or without chemotherapy at the approximately half maximal dose found in the B.5 LX-1 cells, with or without pretreatment with BSO. As shown in Figures 3A and 3B, although melphalan, cisplatin and carboplatin were all somewhat more cytotoxic in the fibroblasts as compared to the tumor cells, nevertheless BSO enhanced the toxicity of all three alkylators. In fibroblasts, N- acetylcysteine was partially to completely chemoprotective against the cytotoxicity induced by melphalan, cisplatin and carboplatin, independent of BSO treatment. As shown in Figure 5, neither BSO cytoenhancement nor N-acetylcysteine chemoprotection affected the cytotoxicity of etoposide phosphate in fibroblasts.
Half-maximal cytotoxic concentrations (EC50) are expressed as pg/ml. Each EC50 measurement comprised 6 concentrations with 4 wells per concentration, and each dose response was performed in triplicate for each chemotherapeutic agent. Data are reported as the mean + pooled standard deviation for three independent experiments. P values are shown ” for the reduction in EC50 by BSO treatment (* = P < 0.05, ** =P < 0.01, *** =P < 0.001).
TABLE 6
Effect of BSO on the cytotoxicity of alkylating chemotherapeutics
Chemotherapy EC50 (ng/ml)
Melphalan Cisplatin Carboplatin
Without BSO 13.8+1.8 89+24 103 + 21 + BSO 6.4 £0.6 ¥** 6.4+09* 55+ 15 ** . Example 8 . Time dependence for chemoprotectant rescue from chemotherapy cytotoxicity
How long the addition of chemoprotectant could be delayed after treatment with chemotherapy and remain effective was evaluated. Cells were treated with doses of chemotherapy providing approximately 90% lethality, for melphalan (20 pg/ml), carboplatin (200 pg/ml), or cisplatin (15 pg/ml). The thiol chemoprotectants were added either concurrently with chemotherapy or up to 8 hours after chemotherapy. For melphalan, chemoprotection was reduced if administration of STS was delayed for 2 hours, whereas sodium thiosulfate was still protective for the platinum chemotherapeutics if delayed up to 4 hours after treatment as shown in Figure 6. Similarly, delayed administration of N- acetylcysteine and glutathione ethyl ester reduced their protective activity against melphalan cytotoxicity, whereas both agents maintained protective activity against platinum cytotoxicity. Separately, all three agents were completely protective if added within 1 hour of melphalan, rather than 2 hours as shown in Figure 6. Chemoprotection was not effective against etoposide phosphate cytotoxicity at any time point.
The time dependence of D-methionine rescue of cisplatin cytotoxicity was also evaluated. Unlike chemoprotection with thiosulfate, N-acetylcysteine, or glutathione ethyl ester, the protection afforded by D-methionine was significantly reduced by delayed administration. If delayed for 2 hours after cisplatin, D-methionine protection was reduced by 41.2 + 10.2 % compared to the maximal protection seen with simultaneous addition, while delaying D-methionine to 4 hours reduced protection by 66.1 + 4.5 % compared with simultaneous addition. Pretreatment with D-methionine for 30 min prior to addition of cisplatin did not increase the amount of protection compared to simultaneous addition.
Example 9 ’ Effects of cytoenhancement and chemoprotection on apoptosis
Apoptosis was evaluated by measuring Caspase-2 enzymatic activity and by in situ
TUNEL staining. Treatment of B.5 LX-1 cells with melphalan resulted in an increase in
Caspase-2 activity that was amplified by BSO pretreatment at low melphalan concentrations as shown in Figure 7A. The increase in caspase activity was variable between experiments and ranged from 50-100% at 7-8 h to 250-600% at 20-24 h after treatment with melphalan.
TUNEL staining also demonstrated melphalan-induced apoptosis. In the experiment shown in Figure 7B, TUNEL staining after melphalan treatment was positive in 29 of 3643 cells, compared to 7 of 4395 cells in the untreated control, and BSO treatment prior to melphalan increased the positive staining to 800 of 1699 cells. In both the caspase-2 assay as shown in
Figure 7A and the TUNEL staining assay as shown in Figure 7B, the effect of melphalan on apoptosis was reduced by the chemoprotectant N-acetylcysteine. In both assays, activity was maximal with low doses of melphalan, or with a 1 hour pulse treatment with the doses used in the cytotoxicity assays. Continuous treatment with the cytotoxic dose of melphalan actually reduced caspase-2 activity and TUNEL staining.
Cisplatin and carboplatin were less effective than melphalan at inducing caspase activity. Over a range of doses (100, 150, or 200 pg/ml carboplatin, and 5, 10, or 15 pg/ml cisplatin) and times (8, 12, 16, 20, 24 h), each platinum agent increased Caspase-2 activity by 50-100%. No significant amplification of caspase activity was induced by BSO treatment.
Additionally, no reduction in caspase enzymatic activity could be detected after addition of
N-acetylcysteine, and in some experiments treatment with N-acetylcysteine actually increased cisplatin- or carboplatin-induced caspase activity. Samples of the cells used in the caspase and TUNEL assays were also evaluated for membrane permeability by trypan blue exclusion. In experiments producing negative results with the caspase-2 or TUNEL assays, trypan blue exclusion showed high numbers of non-viable cells after treatment with carboplatin or cisplatin and this was increased by BSO treatment.
Example 10
Biodistribution of radiolabeled NAC
The method of administration of NAC and its biodistribution was tested. Intra-arterial infusion retrograde via the left external carotid artery, with transient left internal artery occlusion, was evaluated as a mechanism to essentially perfuse via the descending aorta with limited delivery to the brain. When NAC was administered 1.v., negligible amounts were found in brain as determined by the percent administered dose of 14C-NAC per gram of tissue as shown in Figure 8. Intra-arterial delivery in the right internal carotid artery resulted ’ in high levels of radiolabel in the right cerebral hemisphere, and this was not increased by
BBBD. However, aortic infusion minimized brain delivery of NAC as shown in Figure 8.
At the low dose of NAC (140 mg/kg), aortic infusion decreased liver delivery and increased kidney delivery, where as there was no change in liver and kidney delivery at high dose (1200 mg/kg) NAC (data not shown). The serum concentration of NAC 10 min after administration of 1200 mg/kg was 2.4 0.6 mg/ml (n = 6) as determined by radiolabel remaining in the blood.
Example 11
Toxicity of NAC ’ A dose escalation of NAC was performed in the rat. Initial doses of 140-800 mg/kg
NAC administered 1.v. immediately after chemotherapy (n = 4), were well tolerated but provided no detectable bone marrow protection. Doses of NAC above 1200 mg/kg (n = 3) were toxic whereas there was no toxicity at 1200 mg/kg. Therefore, 1200 mg/kg of NAC was used for the bone marrow protection studies, except when administered in conjunction with
STS where a dose of 1000 mg/kg was used due to volume considerations.
The toxicity of NAC was determined when infused for bone marrow protection. As shown in Figure 9. the mortality due to NAC was significantly dependent on the route of administration, with i.v. administration significantly more toxic than aortic infusion (P = 0.0014). Pretreatment with BSO markedly enhanced the toxicity of NAC. Groups given i.v.
NAC after BSO treatment were halted early due to excessive mortality, with a stopping rule of 75% mortality within n= 4 animals. In selected animals (n = 21) from all groups, blood pressure monitoring indicated most animals that expired experienced persistent acute hypotension, suggesting cardiac toxicity. Of particular note, however, there was no mortality nor any evidence of toxicity in 12 animals, without BSO, giving 1200 mg/kg NAC by aortic infusion 30 minutes prior to chemotherapy.
Example 12
Effect of NAC on chemotherapy-induced bone marrow toxicity
Chemoprotection against chemotherapy-induced bone marrow toxicity was determined in BSO treated and untreated animals given i.a. carboplatin, etoposide phosphate, and melphalan. NAC with or without STS was administered either about 30 minutes prior to chemotherapy or immediately after chemotherapy, and was administered either i.v. or by aortic infusion. Chemoprotection was found with NAC as shown by increased blood counts (white blood cells, granulocytes, platelets) at the nadir, compared to no chemoprotectant as shown in Table 7 and Table 8. Chemoprotection was effective whether or not animals were . pretreated with BSO as shown in Figure 10, and the magnitude of the chemotherapy-induced bone marrow toxicity nadir was minimized and recovery to normal platelet levels was improved.
TABLE 7
Protection against chemotherapy-induced myelosuppression
Treatment Rats White Cell Granulocyte Platelet Nadir
Nadir Nadir
No protectant N=6 245 +58 20.7+11.0 227+ 8.7
NAC 1.v. post chemo N=6 46.0 + 6.5* 57.9 + 8.8% 36.8+ 10.4
NAC i.v. 30 min prior N=38 51.4+£94 93.5 +28.1 53.3+ 12.7 ’ NAC aortic infusion post N=6 259+49 36.6 +17.0 26.8+9.3 chemo
NAC aortic infusion 30 N=6 69.7 £19.3 206.2 + 125.1% 593x179 min prior
NAC aortic infusion 30 N=6 53.8 +12.8* 83.4 + 21.3% 47.0 11.5 min prior + STS post chemo
The mean and standard error are shown for nadir blood counts as a percent of baseline. * indicates P<0.05 compared to no protectant, by Wilcoxon/Kruskal-Wallis rank sums tests. :
TABLE 8
Protection against BSO-enhanced chemotherapy-induced myelosuppression
Treatment Rats White Cell Granulocyte Platelet Nadir
Nadir Nadir
No protectant N=11 129+ 3.5 35+13 9.1+£23
NAC aortic infusion post N=7 13.9+42 19.8 + 14.7 11.7+£3.5 chemo
NAC aortic infusion 30 N=9 20.1 £2.7 115.4 + 68.8* 23.1+6.2 min prior
NAC aortic infusion 30 N=7 30.5 £ 6.5% 121.0 + 40.2% 39.0 + 7.4% min prior + STS post chemo
The mean and standard error are shown for nadir blood counts as a percent of baseline. * indicates P<0.05 compared to no protectant, by Wilcoxon/Kruskal-Wallis rank sums tests.
In animals that did not undergo BSO treatment, pretreatment with NAC (1200 mg/kg) by aortic infusion, with or without follow-up with STS, was the best treatment strategy as shown in Figures 10A and 10C. As shown in Figure 10A, the chemotherapy-induced decrease in granulocyte counts was completely blocked (p<0.05) and platelet toxicity was reduced as shown in Figure 10C by aortic infusion of NAC 30 minutes prior to chemotherapy.
In animals pretreated with BSO, good protection for granulocytes was provided by ’ 15 aortic infusion of NAC about 30 min prior to chemotherapy, but the best protection and the least mortality was provided by NAC aortic infusion before and STS immediately after chemotherapy as shown in Figures 10B and 10D. As shown in Figure 10B, the combination chemoprotection (NAC and STS) regimen significantly blocked the toxicity for granulocytes (p<0.01) and, as shown in Figure 10D, platelets (p<<0.01) compared to animals that received no chemoprotection. Chemoprotection also significantly enhanced the platelet recovery from chemotherapy. STS alone did not give consistent bone marrow protection (data not shown).
As noted, the discussion above is descriptive, illustrative and exemplary and is not to be taken as limiting the scope defined by any appended claims.
Claims (42)
1. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck, comprising administering a thiol-based k chemoprotectant agent intra-arterially, wherein the thiol-based chemoprotectant agent
. intra-arterial administration is at a site in the descending aorta or further downstream from the descending aorta, and a cytotoxic agent.
2. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck of claim 1 wherein the cytotoxic agent is a cancer chemotherapeutic agent.
3. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck of claim 2 wherein the cancer chemotherapeutic agent is selected from the group consisting of cis-platinum compounds, taxanes, steroid derivatives, anti-metabolites, vinca alkaloids, adriamycin and doxarubicin, etoposide, arsenic derivatives, intercalating agents, alkylating agents, and combinations thereof.
4. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck of claim 1 wherein the cytotoxic agent (radiation or chemotherapeutic agent) is administered within eight hours of the thiol-based chemoprotectant agent administration.
5. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck of claim 1 wherein the cytotoxic agent is administered such that the majority of the dose is directed to the brain, head or neck region where the tumor is located.
6. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck of claim 1 wherein the thiol-based chemoprotectant agent is administered in a pyrogen-free sterile solution by a catheterization procedure via a catheter having a tip that is located in the descending aorta.
7. The method for treating or mitigating the side effects of cytotoxic cancer ’ therapy for tumors located in the head or neck of claim 1 wherein the dose of the thiol-based chemoprotectant agent per procedure is from about 200 mg/m’ to about 20 g/m’.
8. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck of claim 1 wherein the thiol-based chemoprotectant agent is selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
9. The method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the brain, head or neck of claim 8 wherein the dose of NAC agent per procedure is from about 400 mg/m’ to about 1200 mg/m? and the dose of STS agent ’ is from about 5 g/m? to about 40 g/m’. ,
10. A pharmaceutical composition for treatment of brain, head or neck tumors for administration via arterial catheter comprising: a first agent administered to a carotid artery; and a second agent administered to the descending aorta or further downstream, wherein the first agent is a cytotoxic compound that is used for cancer chemotherapy and causes myelosuppressive side effects systemically, and the second agent is a thiol-based chemoprotectant agent.
11. The pharmaceutical composition for treatment of brain, head or neck tumors for administration via arterial catheter of claim 10 wherein the first agent is selected from the group consisting of cis-platinum compounds, taxanes, steroid derivatives, anti-metabolites, vinca alkaloids, adriamycin and doxarubicin, etoposide, arsenic derivatives, intercalating agents, alkylating agents, and combinations thereof.
12. The pharmaceutical composition for treatment of brain, head or neck tumors for administration via arterial catheter of claim 10 wherein the first agent is administered within eight hours (before, during or after) of the second agent and the second agent is administered in a pyrogen-free sterile solution.
13. The pharmaceutical composition for treatment of head or neck tumors for administration via arterial catheter of claim 10 wherein the dose of the thiol-based chemoprotectant agent per procedure is from about 400 mg/m” to about 1200 mg/m’.
14. The pharmaceutical composition for treatment of head or neck tumors for administration via arterial catheter of claim 10 wherein the thiol-based chemoprotectant agent is selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
15. The pharmaceutical composition for treatment of head or neck tumors for administration via arterial catheter of claim 14 wherein the dose of NAC agent per procedure ’ is from about 400 mg/m? to about 1200 mg/m’.
16. A method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures comprising: positioning an intra-arterial catheter in an artery providing blood flow to a potential site or organ of injury; and administering, via the positioned arterial catheter, a thiol-based chemoprotectant agent.
17. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 16 wherein the injury is caused by injecting radiographic contrast agent to position an intra-arterial catheter. .
18. The method for locally administering a thiol-based chemoprotective agent to . an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 16 wherein the thiol-based chemoprotectant agent is a compound selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, ethyol, and combinations thereof.
19. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 16 wherein the thiol-based contrast-protectant agent is administered in a pyrogen-free, non-oxidized sterile solution by a catheterization procedure via a catheter having a tip that is located in intra-arterially in a position of the circulatory system.
20. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 16 wherein the dose of the thiol-based chemoprotectant agent per procedure is in the range of 200 mg/m2 to 40 g/m?2.
21. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 18 wherein the dose of NAC agent per procedure is in the range of 400 mg/m” to 1200 mg/m’ and the dose of STS is in the range of 5 g/m” to 40 g/m’.
22. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 16 wherein the thiol-based chemoprotectant agent is administered in a pyrogen-free, non-oxidized sterile solution having a reducing agent, a buffer to maintain pH at or near physiologic pH and a metal chelating agent to bind up metal ions that can catalyze oxidation of the thiol-based chemoprotectant agent. r
23. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 22 wherein the reducing agent is selected from the group consisting of vitamin E, tocopherol, dithiotreitol, mercaptoethanol, glutathione, and combinations thereof.
24. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 22 wherein the buffer is one that is relatively non-toxic and can maintain a pH of between 6 and 8.
25. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial
. procedures of claim 16 wherein the thiol-based chemoprotectant agent is stored in a vial having a blanket of an inert gas.
26. The method for locally administering a thiol-based chemoprotective agent to an organ or tissue area to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 25 wherein the inert gas is selected from the group consisting of argon, helium, nitrogen and mixtures thereof.
27. A pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures, comprising a first agent or procedure for intra-arterial administration and a second agent administered intra-arterially, wherein the second agent further comprises a reducing agent or an anti-oxidant.
28. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 27 wherein the first agent is a radiographic contrast agent.
29. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 27 wherein the first agent is administered within eight hours of the second agent.
30. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 27 wherein the second agent is administered in a pyrogen-free sterile solution.
31. The pharmaceutical composition of claim 27 wherein the second agent is a thiol-based chemoprotectant agent.
32. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 31 wherein the thiol-based protectant agent is a compound selected from the group consisting of N-acetyl cysteine ’ (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
33. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 31 wherein the dose of the thiol-based chemoprotectant agent per procedure is in the range of 200 mg/m? to 2000 mg/m’.
34. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 32 wherein the dose of NAC per procedure is in the range of 400 mg/m’ to 1200 mg/m’.
35. The pharmaceutical composition for treatment to protect against injury from
. diagnostic or therapeutic intra-arterial procedures of claim 31 wherein the thiol-based chemoprotectant agent is administered in a pyrogen-free, non-oxidized sterile solution having a reducing agent.
36. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 31 wherein the thiol-based chemoprotectant agent is administered in a buffer to maintain pH at or near physiologic pH.
37. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 31 wherein the thiol-based chemoprotectant agent is administered with a metal chelating agent to bind up metal ions that can catalyze oxidation of the thiol-based chemoprotectant agent.
38. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 35 wherein the reducing agent is selected from the group consisting of vitamin E, tocopherol, dithiotreitol, mercaptoethanol, glutathione, and combinations thereof.
39. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 36 wherein the buffer is one that is relatively non-toxic and can maintain a pH of between 6 and 8.
40. The pharmaceutical composition for treatment to protect against injury from diagnostic or therapeutic intra-arterial procedures of claim 31 wherein the thiol-based chemoprotectant agent is stored in a vial having a blanket of an inert gas.
41. The pharmaceutical composition of claim 40 wherein the inert gas 1s selected from the group, consisting of nitrogen, argon, helium and combinations thereof.
42. The method for locally administering thiol-based chemoprotectant agent to an organ or tissue wherein the organ or tissue is selected from the group consisting of lungs, ' liver, kidneys.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19993600P | 2000-04-26 | 2000-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200208350B true ZA200208350B (en) | 2004-04-08 |
Family
ID=33449302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200208350A ZA200208350B (en) | 2000-04-26 | 2002-10-16 | Administration of a thiol-based chemoprotectant compound. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200208350B (en) |
-
2002
- 2002-10-16 ZA ZA200208350A patent/ZA200208350B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200000844A1 (en) | Administration of a thiol-based chemoprotectant compound | |
AU2001253919A1 (en) | Administration of a thiol-based chemoprotectant compound | |
CA2362281C (en) | Combinations for the treatment of diseases involving angiogenesis | |
US20100227812A1 (en) | Method of supplementing the diet and ameliorating oxidative stress | |
US20150224202A1 (en) | Formulations and uses for microparticle delivery of zinc protoporphyrins | |
AU651624B2 (en) | Enhancement of glutathione levels with glutamine | |
CA2286557A1 (en) | Phorbol esters as anti-neoplastic agents | |
US20110046482A1 (en) | Methods for reducing toxicities associated with medical procedures employing radiographic contrast agents | |
US20040062764A1 (en) | Chemoprotectant for gastric toxicity | |
ZA200208350B (en) | Administration of a thiol-based chemoprotectant compound. | |
WO2002017962A2 (en) | Chemoprotectant for gastric toxicity | |
US20040067952A1 (en) | Method and composition for treatment of cancer | |
US20050267143A1 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof | |
Shapiro et al. | Dose escalation of N, N', N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. | |
EP0874630A1 (en) | Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy | |
AU2002318983A1 (en) | Mathod and composition for treatment of cancer |